AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01504347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent recombinant OspA Lyme Borreliosis Vaccine
Description: 3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
Study NCT02488642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate
Study NCT02488642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study NCT02488642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
Study NCT02488642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
Study NCT02185989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early electrical stimulation and early leg bicycling added to early standard rehabilitation
Study NCT03888118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luna EMG
Description: The duration of the overall therapeutic intervention in both groups will be the same.
Study NCT03133572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Face-mask
Description: In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
Study NCT01535352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom-Net
Description: The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration.
Study NCT01535352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coach-facilitated Treatment as Usual
Description: Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
Study NCT01143987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: starting with 25 mg daily dose with titration, maximum dose 100 mg daily
Study NCT02458989 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Use of a scalpel as a first incision during thyroid operation
Study NCT02458989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery
Description: Use of an electrocautery as a first incision during thyroid operation
Study NCT01707940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg / day
Study NCT01707940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 144807
Description: BI144807 oral solution, intermediate dose
Study NCT00577421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 5 mg tablet of risedronate once a day for 2 years
Study NCT00187733 — intervention group
Intervention type: OTHER
Intervention: Fasting blood and urine collection
Description: Not applicable no drugs dispensed
Study NCT01930396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Study NCT01930396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Study NCT01930396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Tinzaparin)
Description: 0.9% Normal Saline
Study NCT01930396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Unfractionated Heparin)
Description: 0.9% Normal Saline
Study NCT01873898 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rex Medical Closer™ Vascular Closure System
Description: The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
Study NCT02138838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Description: Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
Study NCT02138838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
Study NCT02138838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
Study NCT04853654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: exercise training for 8 weeks
Study NCT02205333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Monotherapy
Description: single intravenous (IV) administration of MEDI6469
Study NCT00780741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Office Probing
Description: Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
Study NCT00780741 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred Facility Probing
Description: Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
Study NCT04327089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor
Study NCT02205333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Plus Tremelimumab
Description: MEDI6469 in combination with Tremelimumab
Study NCT02205333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 Plus Durvalumab
Description: MEDI6469 in combination with Durvalumab
Study NCT02205333 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 plus Rituximab
Description: MEDI6469 in combination with Rituximab
Study NCT01950091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FitBack on-line intervention
Description: On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
Study NCT01950091 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative Website Control
Description: Intervention is a Menu of links to 4 popular Websites offering back pain education
Study NCT01827332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
Study NCT01827332 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
Study NCT02391961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: 10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
Study NCT02391961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
Study NCT01811615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol-free experimental mouth rinse
Study NCT01811615 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol-containing mouth rinsing
Study NCT00134160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Description: Olmesartan medoxomil 40mg/Day
Study NCT00134160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium channel blockers (amlodipine, azelnidipine)
Description: Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
Study NCT01187927 — intervention group
Intervention type: BIOLOGICAL
Intervention: Cervarix®
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Study NCT02548247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orafti® Inulin
Description: Dietary fiber
Study NCT02548247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study NCT01413555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Culture QI Program
Description: The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
Study NCT00674453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: Oral tablet, 0.25 mg, daily, 2 years
Study NCT00674453 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet given once daily for 2 years
Study NCT01471106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day.
Study NCT03774433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences.
Study NCT00368654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Initial dose 5 mg, then 15 mg per week
Study NCT00368654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raptiva
Description: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
Study NCT00368654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
Study NCT00984243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHOTODYNAMIC THERAPY (PDT)
Description: Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm\^2 Excimer-dye laser: 100-200 Joules/cm\^2
Study NCT03795311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX Bevacizumab
Description: In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles.
Study NCT00930566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxsalen
Description: UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient.
Study NCT00930566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracoporal Photopheresis (ECP)
Description: In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient.
Study NCT02796040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02796040 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study NCT01337219 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin
Study NCT05196542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients with apical prolapse who will do Sacro hysteropexy using mersilene tape
Description: comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
Study NCT05196542 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: patients with apical prolapse who will do Sacro hysteropexy using mersilene tape
Description: comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
Study NCT03343873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
Study NCT03343873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
Study NCT03343873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
Study NCT01092182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-R
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles
Study NCT01092182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-RR
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
Study NCT01348555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilatator
Study NCT01348555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bronchodilatator
Study NCT03226977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
Study NCT03226977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
Study NCT04560894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Participants receive SCT-I10A intravenously，200mg，d1，Q3w
Study NCT04560894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510
Description: Participants receive SCT510 intravenously，15mg/kg，d1，Q3w
Study NCT04560894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 200mg
Description: Participants receive sorafenib orally，400mg bid
Study NCT02308488 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
Study NCT00645463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: 20 mg CP-945,598 + 240 mg MR Diltiazem
Study NCT00645463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: 20 mg CP-945,598 alone
Study NCT04317937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jaw opening-closing movements
Description: Jaw opening-closing movements Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Active jaw movements The patient will then perform maximal Jaw opening-closing movements at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active neck exercises While performing the above movements of jaws, the patient will actively perform active neck exercise (head-neck movements in sagittal plane- Extension- Flexion).~Head-Neck extension on jaw opening (Mandible moves vertically downward); and then from Head-Neck extension to natural flexion movement on jaw closing (Mandible moves vertically upward).
Study NCT04317937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific Active exercises
Description: Active neck exercises:~Patient seated on a normal standard comfortable chair with proper back support and feet placed on the floor with no head support.~Note: For Active neck exercise (flexion and extension movements of neck), firstly the patient will perform maximal Jaw opening-closing movements at a pace convenient for his/her for 5 times in order to observe (eyeball observation) the neck extension and flexion as reference point for each individual.~Using this reference points, the patient will ask perform below mentioned active neck exercise.~Active neck exercises: The patient will then perform active neck exercise (flexion and extension of neck) at a pace convenient for his/her for 15 times. Three sets with two minutes rest in between will be ensured.~Active jaw movement: While performing the above movements of neck, the patient will not perform any jaws movements.
Study NCT04317937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: Isometric strengthening exercises For flexion the starting position will be upright head and neck. The patient will be asked to hold this position.~For extension the starting position will be upright head and neck. The patient will be asked to hold this position.~For rotation the starting position will be upright head and neck. The patient will be asked to hold this position.~• In all above movements ( flexion, extension \& rotation) following method will be followed: Manual resistance will then be applied by the investigator by placing the hand on the patient's forehead, posterior part of the head and lateral part of the head with 6 second hold. 15 repetitions of this exercise will be performed. Three sets with one minute rest in between will be ensured.